Generic Colcrys Availability

Colcrys is a brand name of colchicine, approved by the FDA in the following formulation(s):

COLCRYS (colchicine - tablet;oral)

  • Manufacturer: TAKEDA PHARMS USA
    Approval date: July 29, 2009
    Strength(s): 0.6MG [RLD]

Has a generic version of Colcrys been approved?

No. There is currently no therapeutically equivalent version of Colcrys available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Colcrys. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares
    Patent 7,601,758
    Issued: October 13, 2009
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for treating gout flares comprising concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin or erythromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for co-administration of colchicine together with macrolide antibiotics are also provided.
    Patent expiration dates:
    • February 10, 2029
      ✓ 
      Patent use: METHOD OF TREATING GOUT FLARES
  • Methods for concomitant administration of colchicine and macrolide antibiotics
    Patent 7,619,004
    Issued: November 17, 2009
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin or erythromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for co-administration of colchicine together with macrolide antibiotics are also provided.
    Patent expiration dates:
    • December 3, 2028
      ✓ 
      Patent use: METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
  • Methods for concomitant administration of colchicine and a second active agent
    Patent 7,820,681
    Issued: October 26, 2010
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Patent expiration dates:
    • February 17, 2029
      ✓ 
      Patent use: METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
  • Methods for concomitant administration of colchicine and a second active agent
    Patent 7,906,519
    Issued: March 15, 2011
    Inventor(s): Davis; Matthew W.
    Assignee(s): AR Holding Company, Inc.
    Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Patent expiration dates:
    • February 17, 2029
      ✓ 
      Patent use: METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
  • Methods for concomitant administration of colchicine and a second active agent
    Patent 7,915,269
    Issued: March 29, 2011
    Inventor(s): Davis; Matthew W.
    Assignee(s): AR Holding Company, Inc.
    Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Patent expiration dates:
    • February 17, 2029
      ✓ 
      Patent use: METHOD OF TREATING GOUT FLARES
  • Methods for concomitant administration of colchicine and macrolide antibiotics
    Patent 7,935,731
    Issued: May 3, 2011
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
    Patent expiration dates:
    • December 3, 2028
      ✓ 
      Patent use: METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
  • Colchicine compositions and methods
    Patent 7,964,647
    Issued: June 21, 2011
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
    Patent expiration dates:
    • October 6, 2028
      ✓ 
      Patent use: METHOD OF TREATING GOUT FLARES
  • Methods for concomitant administration of colchicine and a second active agent
    Patent 7,964,648
    Issued: June 21, 2011
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Patent expiration dates:
    • October 6, 2028
      ✓ 
      Patent use: FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
  • Colchicine compositions and methods
    Patent 7,981,938
    Issued: July 19, 2011
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
    Patent expiration dates:
    • October 6, 2028
      ✓ 
      Patent use: A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
  • Methods for concomitant administration of colchicine and macrolide antibiotics
    Patent 8,093,296
    Issued: January 10, 2012
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
    Patent expiration dates:
    • October 6, 2028
      ✓ 
      Patent use: METHOD OF TREATING GOUT FLARES
  • Methods for concomitant administration of colchicine and a second active agent
    Patent 8,093,297
    Issued: January 10, 2012
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Patent expiration dates:
    • October 6, 2028
      ✓ 
      Patent use: FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
  • Methods for concomitant administration of colchicine and macrolide antibiotics
    Patent 8,093,298
    Issued: January 10, 2012
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
    Patent expiration dates:
    • October 6, 2028
      ✓ 
      Patent use: METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
  • Methods for concomitant administration of colchicine and macrolide antibiotics
    Patent 8,097,655
    Issued: January 17, 2012
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
    Patent expiration dates:
    • October 6, 2028
      ✓ 
      Patent use: METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
  • Colchicine compositions and methods
    Patent 8,415,395
    Issued: April 9, 2013
    Assignee(s): Takeda Pharmaceuticals U.S.A., Inc.
    Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
    Patent expiration dates:
    • October 6, 2028
      ✓ 
      Patent use: METHOD OF TREATING GOUT FLARES
  • Colchine compositions and methods
    Patent 8,415,396
    Issued: April 9, 2013
    Assignee(s): Takeda Pharmaceuticals U.S.A., Inc.
    Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
    Patent expiration dates:
    • October 6, 2028
      ✓ 
      Patent use: METHOD OF TREATING GOUT FLARES
  • Methods for concomitant administration of colchicine and a second active agent
    Patent 8,440,721
    Issued: May 14, 2013
    Assignee(s): Takeda Pharmaceuticals U.S.A., Inc.
    Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Patent expiration dates:
    • February 17, 2029
      ✓ 
      Patent use: METHOD OF TREATING GOUT FLARES
  • Methods for concomitant administration of colchicine and a second active agent
    Patent 8,440,722
    Issued: May 14, 2013
    Assignee(s): Takeda Pharamceuticals U.S.A., Inc.
    Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Patent expiration dates:
    • February 17, 2029
      ✓ 
      Patent use: METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 29, 2016 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)